BCDANasdaq

BioCardia, Inc.

Healthcare·Oncology·Phase 3·Sunnyvale, CA, United States
OncologyCardiovascularRespiratory

BioCardia, Inc. (BCDA): 7 pipeline candidates · ~2 mo cash runway. Updated within the last hour.

7.8/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway0.5

1.8 months

Financial Health10.0

D/E -2.61 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth10.0

7 candidates

Catalyst MomentumN/A

N/A

Insider Signal10.0

13 buys · 0 sells (180d)

A transparent, data-derived signal for BioCardia, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$12.4M

Cash

$951K

Quarterly Burn

$1.7M

Runway

1.8 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2026
Today~7 mo out
Catalyst within runway

Pipeline (7 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

15

Total value held

$756K

HolderSharesValue
vanguard capital management llc249,182$302K
geode capital management, llc94,287$114K
vanguard fiduciary trust co66,270$80K
citadel advisors llc63,384$77K
susquehanna international group, llp38,827$47K
brown advisory inc35,538$43K
xtx topco ltd24,270$29K
commonwealth equity services, llc18,283$22K
two sigma securities, llc14,780$18K
renaissance technologies llc13,900$17K

Showing top 10 of 15 institutional holders of BioCardia, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·6 FDA decisions·CEO: Dr. Peter A. Altman Ph.D.

Frequently asked questions

How many drug candidates are in BioCardia, Inc.'s pipeline?

BioCardia, Inc. (BCDA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is BioCardia, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, BioCardia, Inc. has approximately 1.8 months of cash runway.

What is BioCardia, Inc.'s market capitalization?

BioCardia, Inc.'s market capitalization is approximately $12.4M.

Who is the CEO of BioCardia, Inc.?

Dr. Peter A. Altman Ph.D. is the chief executive officer of BioCardia, Inc. (BCDA).

Get the full picture on BioCardia, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.